Apotex launches Axitinib Tablets in the U.S., the first generic version of INLYTA®

Apotex announced the U.S. launch of axitinib tablets, the first generic version of INLYTA, in 1 mg and 5 mg strengths. The FDA-approved medicine is an additional treatment option for eligible patients with advanced renal cell carcinoma after one prior systemic therapy has failed. The company noted that axitinib can cause serious adverse reactions and that patients require monitoring during treatment.
Ad
0Like0Dislike0Comments0Shares






Comments 0
No comments yet. Be the first to share your view in the app.
Join the discussion: comments and votes are in the free Beloud app.